INTRODUCTION & OBJECTIVES
Patients with asthma who started ICS/LABA therapy and were treated with a pMDI had higher persistence and adherence rates, better health outcomes and lower health costs from the societal perspective in Spain, being more cost-effectiveness compared to DPI inhalers. The inhaler device selection is very relevant in asthma treatment management, and their proper and continuous training/review is crucial. Despite the study limitations, the study findings where similar to other assessed previously in PC setting patients.
This study has been sponsored by: Patient baseline data are displayed in table 1. No significant differences were found between the two arms. The cohort during the 5-years inclusion period gathered 2,082 asthma patients who started therapy on ICS/LABA (only 27.2% on pMDI device) (Fig.1) . Almost 2/3 of patients were women, and the age (average) was 52.6 years. Treatment adherence on pMDI device was significantly higher throughout the study in asthma patients. The medication possession ratio was 83.1% vs 80.5 % (p < 0.001) ( Table 2) .
METHODS

CONCLUSIONS
RESULTS
Asthma exacerbations were recorded during the 3-year follow-up period.
Patients under pMDI device therapy had significantly less exacerbations (17.7% vs 24.9%; p<0.001) (Fig.3 ) Exacerbation frequency was also recorded. Most of patients (around 70%) had suffered only 1 exacerbation during 3-year time frame, independently from the device, as it is shown on right columns (Fig. 3 ).
On average, asthma patients cost € 6.1 MM, with an average patient cost of €2,887/year. Patient costs/year distribution (€) is displaid in Fig. 4 for asthma patients. The main cost drivers were: drugs (almost 1/3), visits to Primary Care physicians, and indirect costs. Asthma patients treated with ICS/LABA under pMDI also consumed less resources, compared to DPI patients: €2,583 vs €2,938 (p=0.042) Retrospective observational study, based on an administrative Primary Care medical database, wich covers a Health District > 120,000 patients. Asthma patients who started therapy with ICS/LABA were recruited during a 5-year period (2007-2011) and a 3-year follow-up period, who fulfilled some inclusion/exclusion criteria to reflect "Real World Evidence" conditions. Two different cohorts were compared, depending on inhaler device type. The main parameters assessed were: treatment persistence, adherence, asthma exacerbations and resource consumption.
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Asthma is a chronic obstructive respiratory pathology with a high burden of disease and poses a relevant Public Health problem. The most recommended maintenance treatment in persistent asthma patients is the inhaled therapy with inhaled corticosteroids (ICS) and long-acting beta-2 adrenergic (LABA) bronchodilators. Asthma guidelines recommend the fixed dose combinations ICS/LABA use due to its convenience and because it might improve treatment adherence. Hence, these ICS/LABA treatments are widely used.
In fact, almost 3 million fixed-dose ICS/LABA inhalers are prescribed per year for asthma patients in Spain. Fixed dose ICS/LABA inhalers are available in two different inhaler devices: pressurized-metered dose inhalers (pMDI) or dry-powder inhalers (DPI). Each inhaler device type has its own features and handling limitations. Specific and proper training on the inhaler device is crucial to yield asthma control. In Spain, as in most of EU countries, DPI devices are widely used as maintenance therapy (70-80% cases), although pMDIs are used in ≥ 90% as rescue medication (shor-acting beta-adrenergics -SABA-). Nevertheless, there is scarce evidence that this higher usage of DPI inhalers, as maintenance therapy, is based in published evidence that shows higher effectiveness. Additionally, treatment persistence and adherence are critical factors in the therapeutic success in this pathology, and in both cases device selection has a relevant role. OBJECTIVE The aim of this study was to assess treatment persistence and adherence with the combination of ICS/LABA, in the fixed-dose combination inhalers, depending on the inhaler device used: pMDI or DPI, for the treatment of asthma in a real world background. Additionally asthma exacerbations, resources consumption, and associated costs were recorded and analyzed Asthma patients treated with pMDIs showed significant higher therapy persistence on fixed-dose ICS/LABA, compared to the most used DPI devices, throughout the 3-year follow-up period (Fig. 2) 
